Sour IPO Transforms into Sweet JV: Mevion scraps IPO plans but raises $200M and strikes a JV deal with Chinese investors
A proton therapy systems provider has canceled its plans to go public and now plans to form a joint venture (JV) in China supported by a new investment agreement worth up to $200 million.
Cures, budgets and cures for the budget blues
Everybody thinks they're poor, but Uncle Sam does have an ongoing deficit problem, and these budget issues are showing up in interesting ways of late. Needless to say, these problems are affecting the appropriations process, but there may be an escape hatch, and a couple of items of interest for device makers may be at risk, depending on the outcome.
Reversal in regulatory pathway? Europe's changes to CE mark suddenly make FDA-first approval seem attractive
PARIS Later this year, the European Union is almost certain to impose a pre-market authorization procedure for novel high-risk implantable medical devices (Medical Device Daily, July 7 and July 8, 2015).